Rubric Capital Management LP recently filed their 13F report for the third quarter of 2022, which ended on 2022-09-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
767 Third Avenue New York, NY 10017
As of the latest 13F report, the guru’s equity portfolio contained 87 stocks valued at a total of $1.99Bil. The top holdings were GLNG(7.97%), HTZ(6.91%), and FLR(4.14%).
According to GuruFocus data, these were Rubric Capital Management LP’s top five trades of the quarter.
Chimerix Inc
During the quarter, Rubric Capital Management LP bought 875,000 shares of NAS:CMRX for a total holding of 7,500,000. The trade had a 0.08% impact on the equity portfolio. During the quarter, the stock traded for an average price of $1.81.
On 11/15/2022, Chimerix Inc traded for a price of $2.05 per share and a market cap of $180.49Mil. The stock has returned -66.39% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, Chimerix Inc has a price-earnings ratio of 1.17, a price-book ratio of 0.66, a price-earnings-to-growth (PEG) ratio of 0.09, a EV-to-Ebitda ratio of 1.25 and a price-sales ratio of 5.43.
The price-to-GF Value ratio is 0.06, earning the stock a GF Value rank of 2.
Mereo BioPharma Group PLC
During the quarter, Rubric Capital Management LP bought 73,414,480 shares of NAS:MREO for a total holding of 83,780,600. The trade had a 3.53% impact on the equity portfolio. During the quarter, the stock traded for an average price of $0.9882.
On 11/15/2022, Mereo BioPharma Group PLC traded for a price of $0.7477 per share and a market cap of $93.46Mil. The stock has returned -67.49% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, Mereo BioPharma Group PLC has a price-book ratio of 1.17, a EV-to-Ebitda ratio of 1.32 and a price-sales ratio of 0.65.
Radius Health Inc
The guru sold out of their 6,959,305-share investment in NAS:RDUS. Previously, the stock had a 3.79% weight in the equity portfolio. Shares traded for an average price of $10.15 during the quarter.
On 11/15/2022, Radius Health Inc traded for a price of $10.08 per share and a market cap of $480.02Mil. The stock has returned -26.85% over the past year.
GuruFocus gives the company a financial strength rating of 1 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Radius Health Inc has a EV-to-Ebitda ratio of -15.44 and a price-sales ratio of 2.14.
The price-to-GF Value ratio is 0.61, earning the stock a GF Value rank of 10.
Mativ Holdings Inc
The guru established a new position worth 2,456,759 shares in NYSE:MATV, giving the stock a 2.73% weight in the equity portfolio. Shares traded for an average price of $22.89 during the quarter.
On 11/15/2022, Mativ Holdings Inc traded for a price of $19.26 per share and a market cap of $1.06Bil. The stock has returned -39.49% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Mativ Holdings Inc has a price-earnings ratio of 7.80, a price-book ratio of 0.89, a price-earnings-to-growth (PEG) ratio of 1.81, a EV-to-Ebitda ratio of 10.26 and a price-sales ratio of 0.38.
The price-to-GF Value ratio is 0.37, earning the stock a GF Value rank of 4.
Denbury Inc
The guru established a new position worth 558,799 shares in NYSE:DEN, giving the stock a 2.43% weight in the equity portfolio. Shares traded for an average price of $76.64 during the quarter.
On 11/15/2022, Denbury Inc traded for a price of $92.3 per share and a market cap of $4.60Bil. The stock has returned 7.60% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Denbury Inc has a price-earnings ratio of 9.55, a price-book ratio of 3.16, a EV-to-Ebitda ratio of 6.49 and a price-sales ratio of 3.01.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
